Busatto GF, de Araújo AL, Duarte AJDS, Levin AS, Guedes BF, Kallas EG, Pinna FR, de Souza HP, da Silva KR, Sawamura MVY, Seelaender M, Imamura M, Garcia ML, Forlenza OV, Nitrini R, Damiano RF, Rocha VG, Batisttella LR, Carvalho CRR; HCFMUSP PASC Initiative; HCFMUSP Covid-19 Study Group.
COVID-19 may lead to persistent and potentially incapacitating clinical manifestations (post-acute sequelae of SARS-CoV-2 infection (PASC)). Using easy-to-apply questionnaires and scales (often by telephone interviewing), several studies evaluated samples of COVID-19 inpatients from 4 weeks to several months after discharge. However, studies conducting systematic multidisciplinary assessments of PASC manifestations are scarce, with thorough in-person objective evaluations restricted to modestly sized subsamples presenting greatest disease severity.